Analyst Jason McCarthy of Maxim Group maintained a Buy rating on SELLAS Life Sciences Group, with a price target of $7.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in SELLAS Life Sciences Group’s clinical trials and their financial positioning. The company is set to present data from its Phase 2 study of SLS009 in combination with venetoclax and azacitidine at the American Society of Hematology meeting, which has shown positive results in relapsed/refractory acute myeloid leukemia (AML). These results support the advancement of this combination into a later-stage study, planned to begin in the first quarter of 2026.
Additionally, the anticipation of Phase 3 top-line data for galinpepimut-S in complete remission 2 AML by the end of 2025 is seen as a key event for the company’s stock. Financially, SELLAS has strengthened its position by raising $31 million through warrant exercises, providing sufficient funding into the second half of 2026. This financial runway supports the company’s ongoing and future trials, including the initiation of the first-line AML trial for SLS009, thereby underpinning McCarthy’s optimistic outlook and Buy rating.